Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia

Abstract The introduction of ABL Tyrosine Kinase Inhibitors (TKIs) has significantly improved the outcome of Chronic Myeloid Leukemia (CML) patients that, in large part, achieve satisfactory hematological, cytogenetic and molecular remissions. However, approximately 15–20% fail to obtain optimal res...

Full description

Bibliographic Details
Main Authors: Michele Massimino, Stefania Stella, Elena Tirrò, Chiara Romano, Maria Stella Pennisi, Adriana Puma, Livia Manzella, Antonino Zanghì, Fabio Stagno, Francesco Di Raimondo, Paolo Vigneri
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Molecular Cancer
Subjects:
CML
BCR-ABL1
Therapeutic strategies
Immunological approaches
Online Access:http://link.springer.com/article/10.1186/s12943-018-0805-1

Internet

http://link.springer.com/article/10.1186/s12943-018-0805-1

Similar Items